A randomized, open-label study of the effect of Bondronat [ibandronic acid] compared with zoledronic acid on bone turnover, bone resorption, and bone formation in patients with metastatic bone disease from breast cancer.
Phase of Trial: Phase IV
Latest Information Update: 23 Feb 2010
At a glance
- Drugs Ibandronic acid; Zoledronic acid
- Indications Advanced breast cancer; Cancer metastases
- Focus Therapeutic Use
- Sponsors Roche
- 16 Feb 2008 Status changed from in progress to completed.
- 20 Jun 2006 New trial record.